Minervax completes phase II enrollment, wins FDA fast-track status
On a good news day for Minervax, the biotech company developing a group B strep vaccine candidate also reported to have hired a new chief medical officer.
by christian bundgaard, translated by daniel pedersen
It didn’t take long after Danish biotech firm Minervax raised a staggering EUR 72m before the company could announce more news.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
